TLDR
- Pfizer stock falls despite FDA approval for expanded IBRANCE use.
- FDA clears IBRANCE for HR+, HER2+ metastatic breast cancer.
- PATINA trial shows IBRANCE cut progression risk by 24%.
- Approval gives oncologists a new breast cancer maintenance option.
- IBRANCE expands beyond its established HR+, HER2- treatment role.
Pfizer (PFE) secured FDA approval for an expanded IBRANCE treatment combination targeting adults with advanced hormone receptor-positive and HER2-positive breast cancer. The decision adds a maintenance option after induction treatment and addresses a disease subtype with limited dedicated research. Pfizer stock fell 2.59% to $24.08 during Wednesday trading.
FDA Expands IBRANCE Use in Metastatic Breast Cancer
The FDA approved IBRANCE with trastuzumab, endocrine therapy, and optional pertuzumab for eligible adult patients. Doctors can use the combination after patients complete induction treatment for locally advanced or metastatic breast cancer. The approval specifically covers tumors classified as hormone receptor-positive and HER2-positive.
Pfizer based its application on findings from the Phase 3 PATINA clinical trial. Alliance Foundation Trials sponsored the study and assessed IBRANCE during the maintenance treatment phase. Researchers compared the IBRANCE combination against anti-HER2 therapy and endocrine therapy without IBRANCE.
The trial showed that IBRANCE reduced the risk of disease progression or death by 24%. The study reported a hazard ratio of 0.76 and met its statistical target. The results supported adding CDK4/6 inhibition after patients responded to initial treatment.
PATINA Results Support New Maintenance Option
Researchers found that IBRANCE extended the period before cancer progression compared with the existing maintenance approach. The treatment targets resistance that can develop during combined anti-HER2 and endocrine therapy. Oncologists now have another approved option for managing this specific metastatic breast cancer subtype.
The trial reported a safety profile consistent with previous IBRANCE studies and clinical use. Common blood-related events included lower white blood cell levels and reduced neutrophil counts. Other reported events included diarrhea, infections, mouth inflammation, and fatigue, which generally remained mild or moderate.
Researchers previously published the PATINA findings in the New England Journal of Medicine. They also presented the results during the 2024 San Antonio Breast Cancer Symposium. Those disclosures provided detailed evidence supporting the expanded FDA indication.
IBRANCE Approval Builds on Established Treatment Role
Hormone receptor-positive and HER2-positive tumors account for about 10% of all breast cancer cases. Clinicians sometimes describe the subtype as double-positive or triple-positive breast cancer. Researchers have historically conducted fewer dedicated metastatic studies involving this patient group.
PATINA became the first registrational trial to examine CDK4/6 inhibition specifically within this disease subtype. The study evaluated maintenance treatment after patients completed initial therapy and achieved disease control. Its findings now establish a new regulatory pathway for combining IBRANCE with HER2-targeted medicines.
Regulators first approved IBRANCE in 2015 for hormone receptor-positive and HER2-negative metastatic breast cancer. Since then, more than 900,000 patients have received the medicine across global markets. Authorities have also approved IBRANCE in over 100 countries, supporting its established role in metastatic breast cancer care.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
